SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is facing high volatility as investors speculate on the timing of the 80th clinical event, with the community actively debating whether the current price pullback is a healthy consolidation driven by warrant exercises and profit-taking or a sign of deeper fundamental issues. Long-term bulls remain focused on the upcoming REGAL Phase 3 data, while vocal dissenters continue to challenge the company's clinical history and transparency.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market reacts to strong quarterly financial results, including an earnings beat and bullish delivery guidance, which have fueled ongoing community debate over potential stock manipulation. Investors remain sharply divided between those viewing the current share price as a deep-value accumulation opportunity and those frustrated by persistent price volatility despite the company's improving fundamentals.

Applied Digital Corporation

Applied Digital is surging after announcing a significant 15-year hyperscaler lease for its fourth AI campus, fueling community excitement over a growing multibillion-dollar backlog and rising analyst price targets. Shareholders are actively debating the potential for an imminent short squeeze and expressing high conviction in the firm's long-term infrastructure strategy.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a proposed $100 million equity-backed investment from the U.S. government, sparking intense debate between bulls citing national strategic importance and bears pointing to fundamental concerns regarding low revenue and share dilution. The community remains deeply divided, with active discussion focusing on whether this government endorsement signals a long-term sector mandate or merely a volatile momentum play for speculative traders.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing extreme volatility as investors digest a combination of robust growth in its AGI CPU pipeline and concerns over supply constraints that capped near-term expectations. The community remains deeply divided, with many traders debating whether current price swings represent a healthy consolidation for a long-term AI infrastructure play or the bursting of a valuation bubble.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are facing intense selling pressure following a double-beat earnings report, as investors focus on a 17% workforce reduction and concerns regarding competitive pricing headwinds. The community is sharply divided between those viewing the decline as a major buying opportunity due to strong fundamentals and share buybacks, and those fearing structural disruption from AI alternatives impacting the company's core tax software business.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing massive momentum and extreme trading volume following news that the company secured a significant letter of intent for government funding to accelerate its neutral-atom quantum technology. The community is actively debating the company's valuation relative to its peers and the long-term strategic validation provided by federal equity stakes.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating intense debate as it pivots toward AI data center infrastructure through its new solid-state transformer technology, even as the stock faces downward pressure from ongoing challenges in the residential solar sector. While retail investors remain divided between viewing the move as a major long-term re-rating catalyst and concerns over persistent fundamental headwinds, high short interest has turned the ticker into a volatile battleground for active traders.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending following a massive industry-wide rally triggered by reports of a multi-billion dollar U.S. government investment initiative in quantum technology. The community is sharply divided, with bulls pointing to the long-term strategic validation of the sector, while bears criticize the speculative valuations and high cash burn of these companies.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently trading near historical highs as investors lean into the stock as a defensive "safe haven" amidst broader market volatility and inflationary pressures. While the company faces intense scrutiny over its high valuation multiples, the community remains actively divided between those betting on continued growth through retail dominance and those expecting a significant pullback due to stretched fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell? 

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

Ralph Baric And UNC's Biodefense Contract Racket Exposed

Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.

NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

<ul class="summary-bullets"><li>Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements.</li><li>The drugmaker also said that patients who received Nuvaxovid were “twice as likely” to say they would choose the same vaccine again the following year.</li><li>The company maintained its 2026 adjusted revenue outlook of $230 million to $270 million.</li></ul>Shares of Novavax (NVAX) are headed for a breakout week as the vaccine maker reported solid first quarter (Q1) results and spotlighted data showing that patients were “twice as likely” to choose its COVID shot again over a rival vaccine from Moderna<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped 16% on Wednesday to end at $9.36. Shares are eyeing their best week in about nine months.<h2 class="st-heading-2">Novavax Touts Lower Side Effects Vs Moderna</h2>Novavax reported Q1 revenue of $139.5 million, beating analysts’ estimate of $78.3 million. The results were boosted by upfront and milestone payments from licensing and vaccine supply partnerships as the company shifts away from relying primarily on direct COVID vaccine sales.The rally also came as investors focused on fresh data comparing Novavax’s protein-based COVID vaccine, Nuvaxovid, against Moderna’s mNEXSPIKE shot.During the earnings call, Novavax highlighted findings from Sanofi’s head-to-head Phase IV Compare study, which tested Nuvaxovid directly against Moderna’s vaccine. The Maryland-based company said Nuvaxovid showed “statistically fewer side effects compared to mNEXSPIKE, across all prespecified endpoints.”Novavax added that people who received Nuvaxovid were “twice as likely as mNEXSPIKE recipients to say they would definitely choose the same vaccine type again the following year.” The company also pointed to real-world data from the Shield study conducted with the University of Utah, saying that participants who received Nuvaxovid reported fewer side effects and “half as many hours of lost work” compared with recipients of mRNA vaccines.The findings are notable since Novavax’s turnaround depends on its protein-based vaccine as a differentiated alternative in the crowded COVID and future combination flu-COVID market. Novavax believes the combined COVID-flu vaccine market could eventually represent a $10 billion to $12 billion opportunity.<h2 class="st-heading-2">Pfizer, Sanofi Deals Fuel NVAX Optimism</h2>While demand for standalone COVID vaccines has weakened globally, Novavax is leaning on licensing agreements and partnerships to drive growth. The company received a $30 million upfront payment during the quarter from its Matrix-M adjuvant agreement with pfizer. Matrix-M is Novavax’s in-house ingredient that helps the body build a stronger immune response after vaccination.&nbsp;“Despite whatever is happening in the macro environment, there seems to be a very strong interest,” CEO John C. Jacobs said during the conference call. The company said that its partners are currently exploring over 30 infectious disease and cancer indications using Matrix-M.&nbsp;“Our partnerships with Sanofi and Pfizer have the potential on their own, to generate billions in revenue from milestone and royalty opportunities,” Jacobs said. Sanofi is developing combination flu-COVID vaccines using Nuvaxovid under a deal worth at least $1.2 billion.<h2 class="st-heading-2">NVAX Reaffirms 2026 Revenue Outlook</h2>Novavax maintained its 2026 adjusted revenue forecast in the range of $230 million and $270 million, excluding royalties and sales from the Sanofi agreement. The company also reiterated that it expects its existing cash position and partner reimbursements to fund operations into 2028 even without additional milestones or royalty revenue. Novavax posted a Q1 net loss of just $9 million and continues targeting non-GAAP profitability by 2028.&nbsp;After the earnings report and updated vaccine data, TD Cowen raised its price target on Novavax to $9 from $8, still implying a 4% downside from current levels, while maintaining a ‘Hold’ rating. The brokerage cited the Sanofi-led head-to-head study and growing evidence that Nuvaxovid may offer a differentiated tolerability profile compared with other mRNA vaccines.<h2 class="st-heading-2">How Do Retail Traders Feel About NVAX?</h2>On Stocktwits, retail sentiment for NVAX was ‘extremely bullish’ amid over a 430% surge in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_50a26f969e.webp" alt="nvax ss.png" width="968" height="142"><figcaption>NVAX sentiment and message volume as of May 7 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/topstockalerts/message/652530627">said</a>, “not chasing but definitely watching this closely”<stembedurl>https://stocktwits.com/topstockalerts/message/652530627</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bodu/message/652514332">said</a>, “Lean organization, massive $100 billion market. No rush. Im not expecting to be rich tomorrow but I do expect it to happen in a year”<stembedurl>https://stocktwits.com/Bodu/message/652514332</stembedurl>NVAX stock has risen 54% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-es9-launch-drowns-out-fresh-ubs-sell-down/cZXbcphRefg">Nio Stock Jumps In HK: ES9 Launch Buzz Drowns Out Fresh UBS Sell-Down&nbsp;</a>

 Ampoules containing the new Corona vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center. Photo: Matthias Bein/dpa (Photo by Matthias Bein/picture alliance via Getty Images)

NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again 

The company spotlighted new data showing that its COVID vaccine, Nuvaxovid, produced “statistically fewer side effects” than Moderna’s mNEXSPIKE vaccine.

Equity

Sanofi $SNY Shares Sold by UBS Group AG

UBS Group AG reduced its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and...

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised

BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.

Sanofi (NASDAQ:SNY) Sets New 1-Year Low  - Should You Sell?

Sanofi (NASDAQ:SNY) Sets New 12-Month Low - Time to Sell...

Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade

Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade...

M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

M&T Bank Corp trimmed its stake in Sanofi (NASDAQ:SNY - Free Report) by 97.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,531 shares of the company's stock after selling 402,012 shares during the period. M&T Bank Corp's holdi...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest SNY News

SNYSanofi-Aventis